Pharma Wins Offset Moderna Downgrade, Biosimilar Pressures

AbbVie ($ABBV) reported positive late-stage results for its experimental blood cancer therapy etentamig in patients with relapsed or refractory multiple myeloma, meeting the trial's main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators, while also reducing the risk of disease progression. The data adds weight to $ABBV's immunology portfolio and pipeline story, with shares defying recent sell-side downgrades according to analyst commentary.

Pfizer ($PFE) received FDA approval for its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high-risk age groups, contributing to a 30-day share price return of 13.38% and year-to-date return of 14.42%. The 1-year total shareholder return reached 25.63%, lifting the stock to approximately a two-year high. Analysts noted the approval adds to a string of positive updates, though valuation checks suggest the 25.6% one-year gain may already reflect much of the recent optimism.

Moderna ($MRNA) shares fell following a downgrade by Rothschild & Co Redburn analyst Simon Baker to Sell from Neutral on valuation concerns. Baker raised the price target to $81 from $40, representing a 46% downside from the previous day's close of $150.81, according to CNBC reporting.

Merck ($MRK) faces mounting biosimilar pressure on its blockbuster cancer drug Keytruda, which generated $8.4 billion in quarterly sales. Cipla secured exclusive U.S. commercialization rights to Qilu's proposed Keytruda biosimilar ahead of the drug's expected 2028 patent expiration, creating an early map for competition to the franchise. Separately, Fresenius Kabi launched a generic version of $MRK's Sugammadex Injection following the July 2026 expiration of exclusivity for the branded medicine Bridion. The developments underscore the patent cliff dynamics facing major oncology and anesthesia franchises as loss of exclusivity approaches.

Veeva Systems announced that Regeneron ($REGN) and Biogen have adopted its AI-powered Vault CRM suite globally, expanding the company's AI-focused offering across commercial and safety workflows in life sciences. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. The updates highlight how AI-heavy software is becoming core infrastructure for healthcare and biopharma workflows, with major pharmaceutical companies integrating AI capabilities into their commercial and regulatory operations.

Eli Lilly ($LLY) advanced its African market strategy for GLP-1 therapies through a partnership with Aspen. The initiative targets distribution of Mounjaro across Africa, with the initial program representing 1.25% of quarterly sales. While financially small today, the arrangement creates an early framework for GLP-1 expansion across the African continent, demonstrating $LLY's approach to building presence in emerging markets ahead of broader market development.

Johnson & Johnson ($JNJ) returned to the spotlight after a Louisiana jury found the company liable in a talc-related mesothelioma case, adding a fresh layer to its ongoing litigation risk. Despite the verdict, $JNJ posted a 7-day share price return of 4.76% and 30-day return of 9.22%, with the 1-year total shareholder return reaching 59.27%. The momentum suggests investors are weighing litigation risk against the company's broader pharmaceutical and medical device franchises.

Vaxcyte narrowed guidance for its VAX-31 OPUS-1 pivotal trial, with topline safety, tolerability and immunogenicity data now expected by the end of October 2026. The company appointed Luis Jodar, former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases, as Chief Medical Officer, bringing extensive leadership experience across clinical development for pneumococcal conjugate vaccines Prevnar 13 and Prevnar 20. In income-focused positioning, Gilead Sciences ($GILD) offers a 3.98% dividend yield backed by strong profitability and a solid track record, meeting key quality and income criteria for investors seeking exposure to established biotech franchises.